检索结果-南通市图书馆

Capecitabine plus cisplatin treatment in patients with advanced hepatocellular carcinoma

The Chinese-German Journal of Clinical Oncology 2010年第12期9卷 718-723页

作者： Manal M Abdel Wahab Lobna R ezz elarab mohamed a ezz elarab Radiation Oncology and Nuclear Medicine Department Faculty of MedicineAin Shams University National Hepatology and Tropical Medicine Research Institute

Objective： Hepatocellular carcinoma （HCC） is the sixth most common cancer in the world and the third leading cause of cancer related death globally. Parentral treatment of Egyptian patients of bilharziasis contributed to the high incidence of viral hepatitis, and subsequently liver cirrhosis and HCC. CapecJtabJne plus cJsplatJn protocol was evaluated regarding the efficacy and safety in patients with advanced HCC as first line chemotherapy. Methods： One hundred patients with advanced HCC were randomized to receive either capecitabine （1000 mg/m2） twice daily for fourteen days plus intravenous cisplatin （60 mg/m2） on day one to be repeated every three weeks with a maximum of six cycles or placebo （phase III trial）. Results： Baseline characteristics were comparable in both groups. According to Barcelona Clinic Liver Cancer Staging System, stage C was the most predominant （82% vs. 75%） in both groups. Median OS was 12 months versus 10 months in favor of the treated group （P value 〈 0.05）. Median TTP was significantly higher in the chemotherapy group （7 months vs. 4.5 months） as well as disease control rate （40% vs. 29%）, no patient had achieved complete response. Grade 3 toxicity was more pronounced in the treatment group, as regards vomiting and diarrhea （10% vs. 2%）, neurotoxicity （6% vs. 2%）, elevation of aminotransferase and bilirubin （9.8% vs. 4.9%）, hand and foot syndrome reaction was recorded only in chemotherapy group. Conclusion： Capecitabine plus cisplatin regimen showed modest antitumor activity with tolerable toxicity in patients with advanced HCC. Moreover, because of the significantly prolonged time to progression, we demand further attention to this convenient, outpatient, and economic profile based chemotherapy protocol.

关键词： capecitabine cisplatin hepatocellular carcinoma (HCC) bilharziasis liver cirrhosis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：